MEIJI SEIKA PHARMA CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 1916-10-09
- Employees
- 5K
- Market Cap
- -
Clinical Trials
55
Active:9
Completed:28
Trial Phases
4 Phases
Phase 1:14
Phase 2:14
Phase 3:10
+1 more phases
Drug Approvals
14
NMPA:14
Drug Approvals
Cefminox Sodium for Injection
- Product Name
- 美士灵
- Approval Number
- 国药准字HJ20150530
- Approval Date
- Aug 29, 2023
NMPA
Cefminox Sodium for Injection
- Product Name
- 美士灵
- Approval Number
- 国药准字HJ20150529
- Approval Date
- Aug 29, 2023
NMPA
Sodium Hyaluronate Injection
- Product Name
- 玻璃酸钠注射液
- Approval Number
- 国药准字HJ20170243
- Approval Date
- Apr 12, 2022
NMPA
Sodium Hyaluronate Injection
- Product Name
- 玻璃酸钠注射液
- Approval Number
- 国药准字HJ20170211
- Approval Date
- Apr 12, 2022
NMPA
Cefditoren Pivoxil Granules
- Product Name
- 头孢妥仑匹酯颗粒
- Approval Number
- 国药准字HJ20150212
- Approval Date
- Aug 28, 2020
NMPA
Cefditoren Pivoxil Granules
- Product Name
- 头孢妥仑匹酯颗粒
- Approval Number
- 国药准字HJ20150470
- Approval Date
- Aug 28, 2020
NMPA
Cefditoren Pivoxil Granules
- Product Name
- 头孢妥仑匹酯颗粒
- Approval Number
- 国药准字HJ20150211
- Approval Date
- Aug 28, 2020
NMPA
Cefditoren Pivoxil Granules
- Product Name
- 头孢妥仑匹酯颗粒
- Approval Number
- 国药准字HJ20150417
- Approval Date
- Aug 28, 2020
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (41 trials with phase data)• Click on a phase to view related trials
Phase 1
14 (34.1%)Phase 2
14 (34.1%)Phase 3
10 (24.4%)Not Applicable
2 (4.9%)phase_2_3
1 (2.4%)P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
Phase 3
Recruiting
- Conditions
- Hospital-acquired Bacterial PneumoniaComplicated Intra-abdominal InfectionVentilator-associated Bacterial PneumoniaComplicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- Drug: co-administration of cefepime and nacubactamDrug: co-administration of aztreonam and nacubactam
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05905055
- Locations
- 🇯🇵
Meiji Research Site, Nankoku, Kochi, Japan
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
Phase 3
Completed
- Conditions
- Complicated Urinary Tract InfectionAcute PyelonephritiscUTIAP
- Interventions
- Drug: co-administration of aztreonam and nacubactamDrug: imipenem/cilastatinDrug: co-administration of cefepime and nacubactam
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 614
- Registration Number
- NCT05887908
- Locations
- 🇪🇪
Meiji Research Site, Meegomäe, Voru, Estonia
A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT02927353
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02459158
A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595
Phase 1
Completed
- Conditions
- Healthy VolunteersBacterial Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02134834
- Prev
- 1
- 2
- Next
News
No news found